Combining multi-modality data for brain disease diagnosis such as Alzheimer’s disease (AD) commonly leads to improved performance than those using a single modality. However, it is still challenging to train a multi-modality model since it is difficult in clinical practice to obtain complete data that includes all modality data. Generally speaking, it is difficult to obtain both magnetic resonance images (MRI) and positron emission tomography (PET) images of a single patient. PET is expensive and requires the injection of radioactive substances into the patient’s body, while MR images are cheaper, safer, and more widely used in practice. Discarding samples without PET data is a common method in previous studies, but the reduction in the number of samples will result in a decrease in model performance. To take advantage of multi-modal complementary information, we first adopt the Reversible Generative Adversarial Network (RevGAN) model to reconstruct the missing data. After that, a 3D convolutional neural network (CNN) classification model with multi-modality input was proposed to perform AD diagnosis. We have evaluated our method on the Alzheimer’s Disease Neuroimaging Initiative (ADNI) database, and compared the performance of the proposed method with those using state-of-the-art methods. The experimental results show that the structural and functional information of brain tissue can be mapped well and that the image synthesized by our method is close to the real image. In addition, the use of synthetic data is beneficial for the diagnosis and prediction of Alzheimer’s disease, demonstrating the effectiveness of the proposed framework.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.